RTP Mobile Logo
Dissecting the Decision: Investigators Discuss the Available Data and Clinical Factors That Shape the Management of Non-Small Cell Lung Cancer
Released August 2016

Proceedings from a CME symposium held at the 2016 ASCO Annual Meeting. Featuring perspectives from Drs Julie R Brahmer, Roy S Herbst, Suresh S Ramalingam, Martin Reck and Mark A Socinski. (Video Program)

CE Disclosures and Faculty Information

    This activity is intended for hematologists, medical oncologists and other healthcare providers involved in the treatment of non-small cell lung cancer (NSCLC).

    Lung cancer is a devastating disease with broad-reaching impact on public health, as it accounts for 14% of all new cancer cases in the United States and the most cancer-related deaths among both men and women. The number of available cytotoxic chemotherapies exhibiting activity in lung cancer has increased substantially over the past several years, and the development of new therapeutic strategies beyond cytotoxic chemotherapy has been the focus of extensive research and has led to an explosion in lung cancer genetic and biologic knowledge. In addition to the significant strides made in understanding and targeting specific mutations responsible for the pathogenesis of lung cancer, recent insights into how to harness the body’s own immune system are now being applied to the management of this lethal disease. The advent of these treatment options presents new promise of both efficacy and enhanced safety for patients with lung cancer but also challenges practicing oncologists and their support staff to appropriately select individuals who may benefit from these agents and to determine how to integrate such therapies, as they become available, into standard lung cancer treatment algorithms.

    These video proceedings from a CME symposium held during the 2016 ASCO Annual Meeting feature renowned lung cancer clinical investigators weighing in on challenging questions and cases from a panel of community-based general oncologists and reviewing data relevant to the issues raised. By providing information on the latest research developments and their potential application to routine practice, this activity is designed to not only improve clinicians’ knowledge related to the rapidly evolving oncology treatment landscape but also to provide them with practical perspectives to help them become better and more effective caregivers.


    • Design evidence-based strategies for the diagnosis and management of Stage I to III NSCLC, considering the potential contributions of systemic and/or local therapeutic modalities.
    • Compare and contrast expert perspectives on the indications for mutation analysis in patients with localized and metastatic NSCLC, and, when appropriate, use validated testing platforms to obtain this information.
    • Consider age, performance status and other patient- or disease-related factors to guide the selection of induction and maintenance systemic therapy for patients with metastatic nonsquamous NSCLC without an identifiable driver mutation.
    • Assess available research evidence with existing and emerging therapeutic options for patients with advanced squamous cell carcinoma of the lung, and use this information to guide clinical care and protocol opportunities for these individuals.
    • Consider published safety and efficacy data with available and emerging therapeutic strategies, and appropriately incorporate targeted therapies into the care of patients with identified tumor driver mutations or alterations.
    • Describe existing and emerging data on the efficacy and safety of tumor immunotherapy, including approaches directed at the PD-1 and PD-L1 pathways in lung cancer, and consider this information when counseling patients regarding protocol and clinical treatment options.
    • Recall the scientific rationale for ongoing investigation of novel agents or therapeutic approaches in NSCLC, and counsel appropriately selected patients about study participation.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    Research To Practice designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity enables the participant to earn up to 2.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    This CME activity consists of a video component. To receive credit, the participant should watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/ASCOLung16/CME.

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Julie R Brahmer, MD
    Director, Thoracic Oncology Program
    Interim Director
    Johns Hopkins Kimmel Cancer Center at Bayview
    Associate Professor of Oncology
    Sidney Kimmel Comprehensive Cancer Center
    Johns Hopkins School of Medicine
    Baltimore, Maryland

    Advisory Committee: Bristol-Myers Squibb Company, Merck; Consulting Agreements: Bristol-Myers Squibb Company, Celgene Corporation, Lilly, Merck; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, MedImmune Inc.

    Roy S Herbst, MD, PhD
    Ensign Professor of Medicine (Oncology)
    Professor of Pharmacology
    Chief of Medical Oncology
    Director, Thoracic Oncology Research Program
    Associate Director for Translational Research
    Yale Comprehensive Cancer Center
    Yale School of Medicine
    New Haven, Connecticut

    Advisory Committee: AstraZeneca Pharmaceuticals LP, Biothera, Bristol-Myers Squibb Company, Diatech, Genentech BioOncology, Kolltan Pharmaceuticals Inc, Lilly, NotI-microarrays; Consulting Agreements: Merck, Pfizer Inc.

    Suresh S Ramalingam, MD
    Professor of Hematology and Medical Oncology
    Director, Division of Medical Oncology
    Emory University
    Winship Cancer Institute
    Atlanta, Georgia

    Consulting Agreements: Abbott Laboratories, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, Lilly, Merck.

    Martin Reck, MD, PhD
    Head of Department of Thoracic Oncology
    Head of Clinical Trial Department
    LungenClinic Grosshansdorf
    Grosshansdorf, Germany

    Advisory Committee: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Lilly, Novartis Pharmaceuticals Corporation, Pfizer Inc, Roche Laboratories Inc; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Lilly, Pfizer Inc, Roche Laboratories Inc.

    Mark A Socinski, MD
    Executive Medical Director
    Member, Thoracic Oncology Program
    Florida Hospital Cancer Institute
    Orlando, Florida

    Advisory Committee: Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Lilly; Contracted Research: Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, GlaxoSmithKline, Lilly, Merck, Novartis Pharmaceuticals Corporation, Pfizer Inc, Roche Laboratories Inc, Synta Pharmaceuticals Corp; Speakers Bureau: Celgene Corporation, Genentech BioOncology.

    CONSULTING ONCOLOGISTS — The following consulting oncologists (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Philip L Brooks, MD
    EMMC Cancer Care of Maine
    Brewer, Maine

    No relevant conflicts of interest to disclose.

    Shahin Chowdhury, DO
    CTCA (Southeastern Regional Medical Center)
    Newnan, Georgia

    No relevant conflicts of interest to disclose.

    Carl T Henningson, MD
    Regional Cancer Care Associates
    Freehold, New Jersey

    Speakers Bureau: Astellas Pharma Global Development Inc, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Genentech BioOncology.

    Joseph T Martins, MD
    ETMC Cancer Institute
    Tyler, Texas

    No relevant conflicts of interest to disclose.

    Maria Picton, MD
    Physicians East
    Greenville, North Carolina

    No relevant conflicts of interest to disclose.

    MODERATORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma, Agendia Inc, Amgen Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc. 

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

    This activity is supported by an educational grant from Lilly.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: August 2016
    Expiration date: August 2017

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Watch video
(WIFI is recommended for best performance):
Click below to select videos to play: